Is Jounce Therapeutics Inc (JNCE) Stock a Attractive Value?
Wednesday, November 17, 2021 02:30 PM | InvestorsObserver Analysts
Mentioned in this article
Jounce Therapeutics Inc (JNCE) stock is higher by 17.91% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives JNCE stock a score of 69 out of a possible 100.
That rank is chiefly influenced by a fundamental score of 77. In addition to the average rating from Wall Street analysts, JNCE stock has a mean target price of $15.50. This means analysts expect the stock to add 85.41% over the next 12 months. JNCE's rank also includes a long-term technical score of 68. The short-term technical score for JNCE is 61.
JNCE has an Overall Score of 69. Find out what this means to you and get the rest of the rankings on JNCE!
Jounce Therapeutics Inc (JNCE) stock is down -7.11% while the S&P 500 has fallen -0.24% as of 2:28 PM on Wednesday, Nov 17. JNCE has fallen -$0.64 from the previous closing price of $9.00 on volume of 262,569 shares. Over the past year the S&P 500 is up 29.93% while JNCE is higher by 17.91%. JNCE lost -$0.34 per share in the over the last 12 months.
Click Here to get the full Stock Report for Jounce Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
